

JUN 13 1996



K961490

Center Diagnostics

510(k) Summary

-
- Introduction** According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.
-
- 1. Submitter name, address, contact** Boehringer Mannheim Corporation
2400 Bisso Lane
P.O. Box 4117
Concord, CA 94524-4117
(510) 674 - 0690, extension 8415
- Contact Person: Mary Koning
- Date Prepared: April 9, 1996
-
- 2. Device name** Proprietary name: Elecsys® T4 Assay
- Common name: Electrochemiluminescence assay for the determination of total thyroxine (T4).
- Classification name: Radioimmunoassay, Total Thyroxine
-
- 3. Predicate device** We claim substantial equivalence to the Enzymun T4 Assay(K901346).
-
- 4. Device Description** The Elecsys® test principle is based on competition principle. Total duration of assay: 18 minutes (37° C).
- 1st incubation (9 minutes): Sample (15 µL) and a specific anti-T4 antibody labeled with a ruthenium complex (75 µL).
 - 2nd incubation (9 minutes): After addition of biotinylated T4 (75 µL) and streptavidin-coated microparticles (35 µL), the still-free binding sites of the labeled antibody become occupied, with formation of an antibody-hapten complex. The entire complex is bound to the solid phase via interaction of biotin and streptavidin.

Continued on next page



510(k) Summary, Continued

**4.
Device
Description**

•The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier (0.4 second read frame).
•Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent bar code.

**5.
Intended use**

Immunoassay for the in vitro quantitative determination of total thyroxine in human serum and plasma.

**6.
Comparison
to predicate
device**

The Boehringer Mannheim Elecsys® T4 Assay is substantially equivalent to other products in commercial distribution intended for similar use. Most notably it is substantially equivalent to the currently marketed Enzymun T4 Assay (K901346).

The following table compares the Elecsys® T4 Assay with the predicate device, Enzymun T4 Assay. Specific data on the performance of the test have been incorporated into the draft labeling in attachment 5. Labeling for the predicate device is provided in attachment 6.

Similarities:

- Intended Use: Immunoassay for the in vitro quantitative determination of total thyroxine
 - Sample type: Serum and plasma
 - Antibody: Polyclonal Sheep anti-T4 antibodies
 - Solid phase binding principle: Streptavidin/Biotin
 - Assay standardization: GC/MS Gas Chromatography/Mass Spectrometry
-

Continued on next page



510(k) Summary, Continued

6. Comparison to predicate device cont.

Differences:

| Feature | Elecsys® T4 | Enzymun T4 |
|-------------------------|---|---|
| Reaction test principle | Electrochemiluminescence | ELISA/1-step sandwich assay using streptavidin technology |
| Instrument required | Elecsys® 2010 | ES 300 |
| Calibration Stability | A calibration is recommended every 7 days if kit is not consumed; 4 weeks with same reagent lot if reagent is consumed within 7 days. | A calibration is required every run |

Performance Characteristics:

| Feature | Elecsys® T4 | | | Enzymun T4 | | |
|----------------|--------------------------|------------------|------------------|-------------------------|------------|-------------|
| Precision | Modified NCCLS (nmol/L): | | | Modified NCCLS (µg/dL): | | |
| Level | <u>Sample</u> | <u>Control 1</u> | <u>Control 2</u> | <u>Low</u> | <u>Mid</u> | <u>High</u> |
| N | 60 | 60 | 60 | 120 | 120 | 118 |
| Within-Run %CV | 33.39 | 113.10 | 180.55 | 4.55 | 6.79 | 15.49 |
| Total %CV | 4.7 | 2.3 | 2.0 | 2.3 | 2.4 | 2.0 |
| | 33.39 | 113.10 | 180.55 | 4.55 | 6.79 | 15.49 |
| | 6.9 | 3.3 | 2.7 | 3.1 | 2.9 | 2.5 |
| | Modified NCCLS (µg/dL): | | | | | |
| | <u>Sample</u> | <u>Control 1</u> | <u>Control 2</u> | | | |
| N | 60 | 60 | 60 | | | |
| Within-Run %CV | 2.60 | 8.82 | 14.08 | | | |
| Total %CV | 4.7 | 2.3 | 2.0 | | | |
| | 2.60 | 8.82 | 14.08 | | | |
| | 6.9 | 3.3 | 2.7 | | | |

Continued on next page




510(k) Summary, Continued

6. Comparison to predicate device, (cont.)

Performance Characteristics:

| Feature | Elecsys® T4 | Enzymun T4 |
|-----------------------|--|---|
| Lower Detection Limit | 0.23 µg/dL (3 nmol/L) | 0.6 µg/dL (7.7 nmol/L) |
| Linearity | 0.23 - 24.86 µg/dL (3.0 - 320 nmol/L) (with a deviation from a linear line of ±10%) | 0.6 - 25.0 µg/dL (with a deviation from a linear line of ±10%) |
| Method Comparison | Vs Enzymun-Test® T4 <u>Least Squares</u> $y = 1.02x + 0.85$ $r = 0.947$ SEE = 5.39 N = 196 <u>Passing/Bablok</u> $y = 0.93x + 4.55$ $r = 0.947$ SEE = 5.39 N = 196 | Vs Enzymun-Test® T4 <u>Least Squares</u> $y = 0.90x - 0.45$ $r = 0.996$ SEE = 0.648 N = 78 |

Continued on next page



510(k) Summary, Continued

6. Comparison to predicate device, (cont.)

Performance Characteristics:

| Feature | Elecsys® T4 | Enzymun T4 |
|----------------------------|---------------------|---------------------|
| Interfering substances | No interference at: | No interference at: |
| Bilirubin | 25 mg/dL | 64.5 mg/dL |
| Hemoglobin | 1 g/dL | 1 g/dL |
| Lipemia | 1500 mg/dL | 1250 mg/dL |
| Biotin | 30 ng/mL | 200 ng/mL |
| Specificity | % Cross-reactivity | % Cross-reactivity |
| L-T4 | 100 | 100 |
| D-T4 | 100 | 100 |
| L-T3 | 1.53 | 3.5 |
| D-T3 | 1.38 | 2.9 |
| 3-iodo-L-tyrosine | 0.002 | <0.1 |
| 3,5-diiiodo-L-tyrosine | 0.01 | <0.1 |
| tetraiodo-thyroacetic acid | 38.5 | 20 |